Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- General Strategies in Biomarker Research
-
1. The proteomic revolution
- Dr. Larry Gold
-
2. Lipid biomarkers: lipidomics of the macrophage and plasma lipidomes
- Prof. Edward A. Dennis
- New Tools for Biomarker Research
-
5. Development of glyco-biomarkers using glycoproteomics technologies
- Dr. Hisashi Narimatsu
-
6. Circulating nucleic acids as biomarkers in cancer patients
- Prof. Klaus Pantel
- Specific Disease Applications
-
7. Biomarkers in breast cancer
- Prof. Joe Duffy
-
8. Bacterial biomarkers
- Dr. Christiane Honisch
-
9. Diabetes biomarkers
- Prof. Naveed Sattar
-
10. Gene networks, brain networks: understanding schizophrenia
- Dr. Daniel Weinberger
-
11. Biomarkers for Huntington's disease - promises and challenges
- Prof. Sarah Tabrizi
-
12. Update on fluid biomarkers for neurodegenerative diseases
- Prof. Henrik Zetterberg
-
13. Biomarkers in osteoarthritis
- Dr. Ali Mobasheri
- Biomarkers in Drug Discovery and Delivery
-
14. Pharmacogenomics: emphasis on clinical drug development
- Dr. Amelia Warner
-
15. Biomarkers in drug development: potential use and challenges
- Dr. Abdel-Bassett Halim
- Biomarkers in development, nutrition, and health
-
18. Ethnic differences in nutrition
- Prof. Jose Ordovas
-
19. Non-invasive prenatal diagnostics
- Prof. Y. M. Dennis Lo
-
20. Epigenetic biomarkers in cancer
- Prof. Bob Brown
- Archived Lectures *These may not cover the latest advances in the field
-
21. Biomarkers for Alzheimer's disease
- Prof. Henrik Zetterberg
Printable Handouts
Navigable Slide Index
- Introduction
- Biomarkers - what for?
- CVD as exemplar
- Lipids: which ones and when?
- Do apolipoproteins add value?
- CVD risk charts
- Biomarker variety
- CRP, statins and CVD
- NT-proBNP
- CVD biomarkers: prediction benchmark higher
- Prediction lessons from CVD biomarker research
- Pathways for finding biomarkers
- Biomarkers in diabetes - pathogenesis insights
- WOSCOPS: 1.CRP 2.LFT's
- CRP and incident diabetes
- Risk factors for disease
- Liver function as a biomarker
- ALT & incident diabetes
- ALT and incident diabetes: meta-analysis
- ALT as a diabetes biomarker
- Fat accumulation in liver - clinical signs?
- Liver fat vs. alcohol
- Liver disease and other causative factors
- Keeping liver fat low
- Fibre intake and diabetes
- Adiponectin as a biomarker
- Biomarker for pathogenesis: summary
- Biomarkers in diabetes - prediction benefits
- BRHS & BWHHS data >60 year old
- Risk prediction scores
- Biomarkers diabetes prediction summary
- Adiposity prediction confusion
- Combined CVD risk / Diabetes screening
- Biomarkers in diabetes
- 29 RCTs DM patients: simple predictors of risk
- Definition of abnormality
- Biomarkers - complications / treatment guidance?
- Diabetes biomarkers - ready for prime time?
Topics Covered
- For what reason do we need further biomarker research in diabetes?
- Prediction of diabetes
- Prediction of complications
- Personalized therapy
- Biomarkers role in understanding the pathophysiology of diabetes
- Biomarkers and genetics
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Sattar, N. (2013, June 24). Diabetes biomarkers [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/FIDG6245.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Naveed Sattar has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my
name is Naveed Sattar.
I am professor of metabolic medicine
at the University of Glasglow,
and I am going to give you an
overview of diabetes biomarkers.
0:12
So biomarkers, what are they?
And what are they for?
Biomarkers are really any measure,
whether it's biological material
or even a clinical
characteristic which
gives you insight
into either disease,
pathogenesis, prediction of
complications or progression
of follow up. Or it can
actually give you an insight
into the response of an
individual to a particular therapy
or intervention.
So biomarkers can range from simple
things such as age, social class,
but of course, most people
understand the term biomarkers
in terms of some blood measure
or some biochemical parameter,
for example, cholesterol or glucose.
0:52
If we take cardiovascular disease
as an example of how they have used
biomarkers, well, we
are now at a point
where we know that age, blood
pressure, smoking, gender, lipids,
and the presence of diabetes gives
insight into cardiovascular risk.
And from this, we have developed
cardiovascular risk scores,
ranging from the original
Framingham risk scores
through to the risk score in Europe,
as well as more sophisticated risk
scores which have added other
potential parameters which we
will discuss in the
next couple of slides.
There is big-scale epidemiology
on these routine biomarkers
in cardiovascular disease
in terms of prediction.
And some of the lessons we have
learned from cardiovascular disease
in terms of predicting disease
are relevant to diabetes research.
1:34
If we take first the relationship of
lipids to cardiovascular outcomes,
this has now been established
in huge data sets, culminating
in collaboration of multiple
cohorts called Emerging Risk Factor
Collaboration, which reported
the lipid data in 2009 in JAMA,
and shows clearly that
non-HDL or LDL is strongly
and linearly related to hazard
ratio cardiovascular events.
HDL is inversely related, and
triglyceride is positively related
in analysis adjusted for age and sex
only, whilst LDL or non-HDL and HDL
remain associated with CHD in the
same pattern one to further
adjusted for non-lipid
and lipid factors.
Triglyceride actually
shows no association
once other lipid parameters
and another risk factors
are accounted for.
This suggests that actually, LDL and
HDL or total cholesterol and HDL
are all that we really
need in terms of predicting
cardiovascular disease, and
that triglyceride does not
add prediction over and
above other lipid markers.
And in actual fact, further evidence
published in other papers which
suggests that triglyceride
is in fact a stronger risk
factor in the development
of diabetes than it
is for cardiovascular disease.